Big picture - Why invest in Q BioMed Inc
Q BioMed Inc Snapshot
Q BioMed Inc. - Accelerating Biotech Innovations
QBM 001- Q BioMed's answer to a Rare Pediatric Non-verbal Autistic Spectrum Disorder
Our vision is to create a pipeline of innovative biomedical assets in various stages of development in multiple therapeutic areas. Our strategy will minimize risk, share success and accelerate our assets’ technologies to monetization.
We have identified several targets that could provide a substantial pipeline of innovative and high value assets. Q intends to maximize risk-adjusted returns by focusing on clinical stage and innovative products where the technical, regulatory, and commercial risks have been mitigated or major valuation inflections are imminent.
- QbioMed has a growing and diverse pipeline of drugs in development ranging from early pre-clinical to FDA approved and commercial ready.
- Strontium Chloride 89 (FDA Approved) for Bone Cancer pain palliation - COMMERCIALIZING JUNE 2017
- ASD-002 (IND Preparation), a rare pediatric autism spectrum disorder causing mutism in young children (2yrs)
- Uttrocide B (pre-clincail) - New chemical entity for treatment of liver cancer.
- Man-01 (Pre-Clinical) - First in class molecule for treatment of glaucoma.
Q and its investors are positioned to benefit from early investment in illiquid and unknown private assets with multiple potential products in their development cycle and capitalize on valuation growth as they move forward.
Q BioMed Inc is assessing multiple BioMedical assets in various areas of healthcare and drug development. Our Pipeline is not complete and not yet formalized.
We are actively pursuing a pipeline of therapeutics, diagnostics and orphan drug candidates that we believe will provide a robust technology platform from which to build significant value.
For information on Strontium Chloride Sr-89, please click here
For information on Man 01 - Glaucoma, please click here
For information on Uttrocide B, please click here
PLEASE CLICK HERE TO READ THE ARTICLE ON Q BIOMED INC. FINALIZES LICENSE AGREEMENT WITH OKLAHOMA MEDICAL RESEARCH FOUNDATION AND THE RAJIV GANDHI CENTRE FOR BIOTECHNOLOGY FOR NOVEL LIVER CANCER TREATMENT
Denis D Corin - CEO and Chairman
Mr. Denis D. Corin is our Chief Executive Officer and Chairman of the Board. Mr. Corin is an experienced public company executive and management consultant. He has worked almost exclusively in the biomedical field for over 13 years from large pharma and diagnostic companies to small innovative biotech. He has served in various senior executive roles and has been instrumental is building and restructuring businesses. Mr. Corin has raised millions of dollars in development capital to advance businesses. Mr. Corin also served as a Management Consultant to the executives and board of TapImmune Inc., a clinical stage immune-oncology company through 2014, where had previously served as CEO and President. He has been a Director of Q BioMed, Inc. since April 2015. He served as a Director of TapImmune Inc., from July 2009 to May 2012. He continues to serve as a Director of Soloro Gold and NPX Metals Inc. He holds a Bachelors Degree majoring in both Economics and Marketing & Advertising Management from the University of Natal, South Africa.
William Rosenstadt - General and Corporate Securities Counsel and Director
William Rosenstadt is the founding and managing partner of Sanders Ortoli Vaughn-Flam Rosenstadt LLP an international law firm located in New York and has been a practicing attorney since 1995. William advises entrepreneurs, public companies, and other corporate entities with respect to the execution of complex commercial, corporate, and international transactions. William often serves as general counsel to his clients advising them with respect to public and private financings (equity and debt), federal securities law compliance and other merger and acquisition related transactions. Mr. Rosenstadt and his firm are authorized to sponsor issuers on the OTC Markets as Principal American Liaisons (“PAL”) and Designated Advisors for Disclosure (“DAD”) and were instrumental in introducing the Canadian Securities Exchange to the OTC Markets and having it designated as an authorized exchange. Early in his legal career, Mr. Rosenstadt was general counsel to American Industrial Acquisition Corporation, a private equity firm focused on investing in privately held, middle market manufacturers in the wire/cable and defense industries. Mr. Rosenstadt graduated from Syracuse University with a B.A. in 1990 and received his J.D. from the Benjamin N. Cardozo School of Law in 1995. Further, he is admitted to the bars of New York, New Jersey, and Connecticut as well as the Second Circuit of the federal courts of the United States.
Ari Jatwes - Corporate Advisor and Senior Analyst
Ari Jatwes is an analyst and a banker, with over twenty years of experience. He began his career in a large accounting firm, progressing to a reputable investment bank, where he gained his tremendous experience in mergers and acquisitions. Over the last decade Ari’s interest and focus has been in the biotech and pharma sector, which included trading biotech stocks from start up to late stage biotech companies, advising management and raising capital for their needs. Ari has played an integral role in several successful contracts and transactions in the healthcare space – with emphasis on the life sciences and immunotherapy. Mr. Jatwes holds two Master degrees and a Bachelor Degree from the University of South Africa and the University of Natal.
David Laskow-Pooley - VP Scientific & Product Development
Mr. Laskow-Pooley has 30 years of experience in all aspects of the discovery, development and commercialization of pharmaceutical products, diagnostics and devices. He is an industry veteran and has a distinguished career working for numerous pharmaceutical and life sciences companies. David has held director, executive officer and general management posts in both small and major multinational companies including GSK, Abbott, Amersham plc, Life technologies, OSI, Bilcare and Surface Therapeutics.
SHARES ISSUED: 8,975,000
MANAGEMENT/INSIDER OWNERSHIP: 3,8 M (47.7%)
WARRANTS & OPTIONS: 650,000
AUTHORIZED: 250,000,000 COMMON
AUTHORIZED: 100,000,000 PREFERRED